Adipocytes as Orchestrators of Multimodal Cancer Therapy Resistance
Authors:
Open Access
- 30 April 2026
- journal article
- review article
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 34 (3) , 491-505
Abstract
Jinseon Park and Jaebeom Cho. Biomolecules & Therapeutics 2026;34:491-505. https://doi.org/10.4062/biomolther.2026.036Keywords
Funding Information
- National Research Foundation of Korea (RS-2025-24535434)
This publication has 99 references indexed in Scilit:
- Three-dimensional cell culture: the missing link in drug discoveryDrug Discovery Today, 2013
- Adipose tissue heterogeneity: Implication of depot differences in adipose tissue for obesity complicationsMolecular Aspects of Medicine, 2013
- Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast CancerPLOS ONE, 2012
- Adipokines in inflammation and metabolic diseaseNature Reviews Immunology, 2011
- Subcutaneous and visceral adipose tissue: structural and functional differencesObesity Reviews, 2009
- Tumor necrosis factor and cancer, buddies or foes?Acta Pharmacologica Sinica, 2008
- Relationship Between Obesity and Pathologic Response to Neoadjuvant Chemotherapy Among Women With Operable Breast CancerJournal of Clinical Oncology, 2008
- Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cellsBiochemical and Biophysical Research Communications, 2006
- Adipose Tissue as an Endocrine OrganThe Journal of Clinical Endocrinology & Metabolism, 2004
- The hormone resistin links obesity to diabetesNature, 2001